HOME >> MEDICINE >> NEWS
Shire receives approvable letter for adult ADDERALL XR(R) from FDA

Rockville, Maryland US October 20, 2003 Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the US Food and Drug Administration (FDA) for ADDERALL XR (R) once daily treatment for adult Attention Deficit Hyperactivity Disorder (ADHD).

The Supplemental New Drug Application (sNDA), which was submitted to the FDA on 18 December 2002, included a comprehensive clinical programme in adult patients and supplements the largest ever open-label community assessment trial in pediatric ADHD research. ADDERALL XR is patented until 2018 and the adult indication is expected to receive a three-year Hatch-Waxman protection.

ADDERALL XR is a once daily formulation containing the same active ingredients as ADDERALL (R) (mixed salts of a single entity amphetamine product), which was developed by Shire's drug delivery division, Shire Laboratories Inc., using the Microtrol (R) oral controlled release technology. Shire already successfully markets ADDERALL XR for pediatric use in the US where it is recognized as the ADHD brand leader.

The adult market is roughly twice the size of the pediatric market 1. Approximately 66 pecent 2 of children with ADHD will continue to suffer from the disease throughout their adult life. The National Institute of Mental Health reported in 1999 that ADHD affected 8.2 million adults in the US, of which only 360,000 patients were receiving treatment. Non-treated, this disease can lead to psychological maladjustment, as well as occupational and social disability. Appropriate diagnosis and treatment of ADHD in adults helps improve self-esteem, work performance and skills, educational attainment and social competencies.

Dr Wilson Totten, Group R&D Director, said: "This is great news for adult ADHD patients and will give them a new choice of treatment which has already been widely successful with children. This further step for Shi
'"/>

Contact: Michele Roy, Shire
450-978-7938
Porter Novelli
20-Oct-2003


Page: 1 2

Related medicine news :

1. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Shire receives approvable letter for adult ADDERALL from FDA

(Date:5/24/2013)... News) -- Drugs commonly used to treat glaucoma may ... interfere with vision, according to a new study. ... used to reduce eye pressure, have already been shown ... color, the researchers said, suggesting that the new findings ... Doctors should be conservative when prescribing these drugs, the ...
(Date:5/24/2013)... Let’s face it: very few are luckily ... the majority of people to be uncomfortable with the color ... coffee addiction or simply genetics, yellowish or stained teeth suppresses ... , Herald Square Dental is proud to announce ... Venus White Max. , Teeth become discolored for a ...
(Date:5/24/2013)... Chino, CA (PRWEB) May 24, 2013 Area ... huge selection of new hot tubs to choose from at ... Super Sale . The sales event takes place at ... May 26, 2013. , Jacuzzi, the industry's leading hot ... sale traveling across the country. The event will feature popular ...
(Date:5/24/2013)... New York (PRWEB) May 24, 2013 ... lawsuit involving Intuitive Surgical Inc.’s da Vinci Surgical ... to court records, a Washington State Court jury ruled ... negligence in training a surgeon who performed a da ... later. The patient’s family had alleged in their ...
(Date:5/24/2013)... development of infantile myofibromatosis (IM)a disorder characterized by multiple ... new therapeutic targets, according to researchers from the Icahn ... in the American Journal of Human Genetics , ... disease, for which the only current treatment option is ... an inheritied disorder that develops in infancy or even ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2
(Date:5/23/2013)... SAN DIEGO y PARÍS, 24 de ... VOLC ), un destacado desarrollador y fabricante ... para mejorar la diagnosis y tratamiento de la ... resultados preliminares del ensayo ADVISE ( Ad enosine ... tenosis E valuation) II durante la sesión ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: